26 Recruiting Primary Myelofibrosis Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceTop Recruiting Primary Myelofibrosis Studies
CINC424A2X01B Rollover Protocol
📍 Novartis Investigative Site — Darlinghurst, New South Wales
View Study & Checklist ➔Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
📍 GSK Investigational Site — Ann Arbor, Michigan
View Study & Checklist ➔Myeloproliferative Neoplasms (MPNs) Patient Registry
📍 Princess Margaret Cancer Centre — Toronto, Ontario
View Study & Checklist ➔Study of Canakinumab in Patients With Myelofibrosis
📍 Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
View Study & Checklist ➔Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Decitabine in Treating Patients With Myelofibrosis
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
📍 University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
📍 Stanford Cancer Institute — Palo Alto, California
View Study & Checklist ➔